Advertisement

Related Videos

Focus on Optimized Dosing of Ibrutinib Panel Discussion

The Interventional Pharmacoeconomic Toolbox Panel Discussion

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Opportunities to Optimize Cancer Policies Panel Discussion

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Advertisement

Advertisement




Apr
09
Today In Oncology
Small Phase II Study Examines Triplet Regimen for Patients With HER2-Positive Breast Cancer and Leptomeningeal Metastasis
Long-Term Outcomes With Pralsetinib in RET Fusion–Positive NSCLC
IMPT vs IMRT in Oropharyngeal Cancer
Metastatic Papillary Renal Cancer Final Results With Savolitinib and Durvalumab
Damaging Missense Variants in Innate Immunity Genes Linked to Earlier Breast Cancer Onset in BRCA1 Carriers
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo